Literature DB >> 25209860

Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat.

Marcel Dautzenberg1, Antje Kahnert2, Johannes-Peter Stasch2, Armin Just3.   

Abstract

We studied the influence of soluble guanylate (sGC) on renal blood flow (RBF), glomerular filtration rate (GFR), and RBF autoregulation and its role in mediating the hemodynamic effects of endogenous nitric oxide (NO). Arterial pressure (AP), heart rate (HR), RBF, GFR, urine flow (UV), and the efficiency and mechanisms of RBF autoregulation were studied in anesthetized rats during intravenous infusion of sGC activator cinaciguat before and (except GFR) also after inhibition of NO synthase (NOS) by Nω-nitro-L-arginine methyl ester. Cinaciguat (0.1, 0.3, 1, 3, 10 μg·kg(-1)·min(-1), n=7) reduced AP and increased HR, but did not significantly alter RBF. In clearance experiments (FITC-sinistrin, n=7) GFR was not significantly altered by cinaciguat (0.1 and 1 μg·kg(-1)·min(-1)), but RBF slightly rose (+12%) and filtration fraction (FF) fell (-23%). RBF autoregulatory efficiency (67 vs. 104%) and myogenic response (33 vs. 44 units) were slightly depressed (n=9). NOS inhibition (n=7) increased AP (+38 mmHg), reduced RBF (-53%), and greatly augmented the myogenic response in RBF autoregulation (97 vs. 35 units), attenuating the other regulatory mechanisms. These changes were reversed by 77, 78, and 90% by 1 μg·kg(-1)·min(-1) cinaciguat. In vehicle controls (n=3), in which cinaciguat-induced hypotension was mimicked by aortic compression, the NOS inhibition-induced changes were not affected. We conclude that sGC activation leaves RBF and GFR well maintained despite hypotension and only slightly impairs autoregulation. The ability to largely normalize AP, RBF, RBF autoregulation, and renovascular myogenic response after NOS inhibition indicates that these hemodynamic effects of NO are predominantly mediated via sGC.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  cGMP; cinaciguat; glomerular filtration rate; nitric oxide; renal blood flow autoregulation; renal hemodynamics; sGC activation; soluble guanylate cyclase

Mesh:

Substances:

Year:  2014        PMID: 25209860     DOI: 10.1152/ajprenal.00229.2014

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  5 in total

1.  Nitric Oxide Signalling in Descending Vasa Recta after Hypoxia/Re-Oxygenation.

Authors:  Minze Xu; Falk-Bach Lichtenberger; Cem Erdoǧan; Enyin Lai; Pontus B Persson; Andreas Patzak; Pratik H Khedkar
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

2.  Modulation of the myogenic mechanism: concordant effects of NO synthesis inhibition and O2- dismutation on renal autoregulation in the time and frequency domains.

Authors:  Nicholas G Moss; Tayler K Gentle; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-28

3.  Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.

Authors:  John P Hanrahan; Ian H de Boer; George L Bakris; Phebe J Wilson; James D Wakefield; Jelena P Seferovic; Jennifer G Chickering; Yueh-Tyng Chien; Kenneth Carlson; Michael D Cressman; Mark G Currie; G Todd Milne; Albert T Profy
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-16       Impact factor: 8.237

4.  Impact of the NO-Sensitive Guanylyl Cyclase 1 and 2 on Renal Blood Flow and Systemic Blood Pressure in Mice.

Authors:  Evanthia Mergia; Manuel Thieme; Henning Hoch; Georgios Daniil; Lydia Hering; Mina Yakoub; Christina Rebecca Scherbaum; Lars Christian Rump; Doris Koesling; Johannes Stegbauer
Journal:  Int J Mol Sci       Date:  2018-03-23       Impact factor: 5.923

5.  Redox regulation of hemodynamics response to diadenosine tetraphosphate an agonist of P2 receptors and renal function in diet-induced hypercholesterolemic rats.

Authors:  Kamil Dąbkowski; Ewelina Kreft; Kornelia Sałaga-Zaleska; Gabriela Chyła; Agnieszka Kuchta; Maciej Jankowski
Journal:  Physiol Rep       Date:  2021-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.